Actelion Pharmaceuticals, Ltd. v. Iancu, No. 17-1238 (Fed. Cir. Feb. 6, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Actelion Pharmaceuticals, Ltd. (“Actelion”) ap peals from the grant of summary judgment by the United States District Court for the Eastern Dis trict of Virginia in favor of the United States Patent and Trademark Office (“PTO” ) regarding the length of the patent term adjustment (“PTA”) for U.S. Patent 8,658,675 ( “the ’675 patent”), entitled “Pyridin -4-yl Derivatives.” See Actelion Pharm., Ltd. v. Lee , 216 F. Supp. 3d 680 (E.D. Va. 2016). For the reasons that follow, we affirm. BACKGROUND Congress has established a framework in 35 U.S.C.